In the Treatment of Congenital Fibrinogen Deficiency (CFD)
Fibryga is a human fibrinogen indicated for the treatment of acute bleeding episodes in adults and adolescents with congenital fibrinogen deficiency, including afibrinogenemia and hypofibrinogenemia.1
Fibryga is not indicated for dysfibrinogenemia.1
Fibryga is a
purified, virus-inactivated and nanofiltered (20 nm) human
Effective bleeding control
For the first time in this rare
disease setting, objective efficacy criteria were used as a robust method to determine hemostatic efficacy of fibryga.2
- Fibryga full Prescribing Information. Paramus, NJ: Octapharma; rev 2020.
- Lissitchkov T, Madan B, Djambas Khayat C, et al. Efficacy and safety of a new human fibrinogen concentrate in patients with congenital fibrinogen deficiency: an interim analysis of a Phase III trial. Transfusion. 2018;58:413-422.